Sharon Shiraga, MD, FACS

Articles by Sharon Shiraga, MD, FACS

Ensuring Comprehensive Support and Long Term Success for Patients Receiving DFLOT

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

January 19th 2026

Discover how specialized cancer care, including nurse navigators and telehealth, enhances patient outcomes and quality of life post-treatment.

Managing Toxicity, Monitoring Needs, and Logistical Realities of DFLOT in Perioperative Care

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

January 19th 2026

Experts discuss the management of immune-mediated side effects in perioperative cancer treatment, emphasizing patient care and monitoring strategies.

Applying DFLOT to a Real World Case of Resectable Stage III GE Junction Cancer

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

January 12th 2026

Explore the complexities of managing a Stage 3 gastric adenocarcinoma case, focusing on surgical options and perioperative treatment strategies.

Strengths, Limitations, and Real World Adoption of the MATTERHORN DFLOT Strategy

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

January 12th 2026

Experts discuss the strengths and limitations of the Matterhorn study, highlighting advancements in immunotherapy for upper GI cancer and future research directions.

Counseling Patients on PCR, Residual Disease, and the Role of Adjuvant Therapy After DFLOT

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

January 5th 2026

Oncologists discuss the significance of PCR and MPR rates in patient counseling, emphasizing treatment benefits and survival outcomes.

Integrating PD-L1 Testing and Practical Implications for DFLOT Adoption

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

January 5th 2026

Experts discuss the importance of PD-L1 testing in treatment decisions for gastric cancer, emphasizing personalized approaches and improved patient outcomes.

Interpreting Overall Survival and Subgroup Outcomes in MATTERHORN: Where DFLOT Shows Strength and Where Questions Remain

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 29th 2025

Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing patient quality of life and treatment decisions.

Interpreting Endpoints and Pathologic Response: Applying EFS, PCR, and Biomarkers in Perioperative Decision Making

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 29th 2025

Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing the importance of patient quality of life.

DFLOT Implementation: Surgical Timing, Patient Selection, and the Evolving Role of Adjuvant Immunotherapy

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 22nd 2025

Doctor Fontaine discusses the importance of patient selection for preoperative chemotherapy and the effectiveness of immune checkpoint inhibitors in surgery outcomes.

MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 22nd 2025

Experts discuss the challenges and strategies in managing patients with inadequate responses to preoperative cancer treatments, emphasizing the need for clinical trials.

Managing FLOT Tolerability, Assessing Pathologic Response, and Addressing Unmet Needs in the Perioperative Setting

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 15th 2025

Experts discuss the challenges and strategies in managing patients with inadequate responses to preoperative cancer treatments, emphasizing the need for clinical trials.

Evaluating Total Neoadjuvant Approaches: Balancing Treatment Intensity, Surgical Timing, and Patient Selection

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 15th 2025

Experts discuss tailored approaches to neoadjuvant therapy for esophageal and gastroesophageal junction cancers, emphasizing multidisciplinary care and surgical precision.

Selecting Neoadjuvant Strategies for Esophageal and GEJ Adenocarcinoma Across Multidisciplinary Practices

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 8th 2025

Experts discuss tailored approaches to neoadjuvant therapy for esophageal and G-junction cancers, emphasizing the importance of multidisciplinary care.

Current Standards in Resectable Gastric and GEJ Adenocarcinoma: Multidisciplinary Perspectives on Perioperative Management

ByRutika Mehta, MD, MPH,Sharon Shiraga, MD, FACS,Sreenivasa R. Chandana, MD, PhD,Jacques-Pierre Fontaine, MD

December 8th 2025

Explore the evolving landscape of cancer treatment strategies, focusing on guideline-based management and the impact of multimodal approaches on patient outcomes.

Latest Updated Articles

MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice
Published: December 22nd 2025 | Updated:
Evaluating Total Neoadjuvant Approaches: Balancing Treatment Intensity, Surgical Timing, and Patient Selection
Published: December 15th 2025 | Updated:

Sharon Shiraga, MD, FACS

Articles by Sharon Shiraga, MD, FACS

Ensuring Comprehensive Support and Long Term Success for Patients Receiving DFLOT

Managing Toxicity, Monitoring Needs, and Logistical Realities of DFLOT in Perioperative Care

Applying DFLOT to a Real World Case of Resectable Stage III GE Junction Cancer

Strengths, Limitations, and Real World Adoption of the MATTERHORN DFLOT Strategy

Counseling Patients on PCR, Residual Disease, and the Role of Adjuvant Therapy After DFLOT

Integrating PD-L1 Testing and Practical Implications for DFLOT Adoption

Interpreting Overall Survival and Subgroup Outcomes in MATTERHORN: Where DFLOT Shows Strength and Where Questions Remain

Interpreting Endpoints and Pathologic Response: Applying EFS, PCR, and Biomarkers in Perioperative Decision Making

DFLOT Implementation: Surgical Timing, Patient Selection, and the Evolving Role of Adjuvant Immunotherapy

MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice

Managing FLOT Tolerability, Assessing Pathologic Response, and Addressing Unmet Needs in the Perioperative Setting

Evaluating Total Neoadjuvant Approaches: Balancing Treatment Intensity, Surgical Timing, and Patient Selection

Selecting Neoadjuvant Strategies for Esophageal and GEJ Adenocarcinoma Across Multidisciplinary Practices

Current Standards in Resectable Gastric and GEJ Adenocarcinoma: Multidisciplinary Perspectives on Perioperative Management

Latest Updated Articles

Trending on CancerNetwork

Novel Vaccine Combo Shows Responses in Recurrent Epithelial Ovarian Cancer

FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer

Firmonertinib Demonstrates Promise in EGFR+ Advanced/Metastatic NSCLC

FDA Accepts NDA for Bezuclastinib Combo in Gastrointestinal Stromal Tumors

FDA Issues Guidance on MRD, CR Outcomes for Multiple Myeloma Approvals